Breast cancer therapies currently rely on traditional methods such as surgery, chemotherapies, and radiotherapy, alongside more targeted approaches, including endocrine therapies, HER2 inhibitors, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and immunotherapies [4]. This evidence concerns the gene PARP1 and breast carcinoma.